Central Nervous System Parasitic Infections: Clinical Trials

10 trials for Central Nervous System Parasitic Infections, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 recruiting, 1 withdrawn. 10 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 110Completed 8, Recruiting 1, Withdrawn 1
Phase 22Completed 1, Recruiting 1

Follow Central Nervous System Parasitic Infections: new trials by email Literature Review of Central Nervous System Parasitic Infections trials Research Report on Central Nervous System Parasitic Infections

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
DON in Pediatric Cerebral Malaria
6-diazo-5-oxo-L-norleucine (DON), Placebo - Malaria, Cerebral
Phase 1 / Phase 2RecruitingDouglas Postels, MD, MS1522022-08-162026-10-23
Single Ascending Dose Safety Study of Oxfendazole
oxfendazole, placebo - Tenia Solium Infection
Phase 1WithdrawnJohns Hopkins Bloomberg School of Public Health2016-08-012016-08-30
Phase I Trial Evaluating the Safety and Pharmacokinetics of Oxfendazole
Oxfendazole, Placebo - Neurocysticercosis
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)702014-11-172020-11-02
Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria
LEVETIRACETAM - Seizure, Epilepsy
Phase 1 / Phase 2CompletedUniversity of Rochester72013-01-012016-09-15
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [F-18]FB
[F-18]FBR - Neurocysticercosis, Healthy
Phase 1CompletedNational Institute of Mental Health (NIMH)242007-09-042018-07-05
PET Imaging of Peripheral Benzodiazepine Receptors in Patients With Neurocysticercosis Using [C-11]PBR28
[C-11]PBR28 - Neurocysticercosis, Healthy
Phase 1CompletedNational Institute of Mental Health (NIMH)182007-09-042019-12-12
Study of the Safety of Intravenous Artesunate
Intravenous Artesunate, Placebo - Malaria, Malaria, Cerebral
Phase 1CompletedU.S. Army Medical Research and Development Command262006-06-122018-10-25
A Study of Pyrimethamine in the Treatment of Infection by a Certain Parasite in HIV-Positive Patients
Pyrimethamine, Leucovorin calcium, Zidovudine - Toxoplasmosis, Cerebral, HIV Infections
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)262021-11-04
Study of the Safety of Intravenous Artesunate
Intravenous artesunate - Malaria, Malaria, Cerebral
Phase 1CompletedU.S. Army Medical Research and Development Command402016-10-26
A Study of Azithromycin Plus Pyrimethamine in the Treatment of a Brain Infection in Patients With AIDS
Azithromycin, Pyrimethamine, Leucovorin calcium - Toxoplasmosis, Cerebral, HIV Infections
Phase 1CompletedPfizer452008-08-26

Narrower conditions

Malaria, Cerebral (4)  ·  Neurocysticercosis (4)  ·  Taeniasis (4)  ·  Epilepsy (3)  ·  Malaria (3)  ·  Encephalitis (2)  ·  HIV Infections (2)  ·  Neuroinflammatory Diseases (2)  ·  Toxoplasmosis (2)  ·  Toxoplasmosis, Cerebral (2)  ·  Acquired Immunodeficiency Syndrome (1)  ·  Malaria, Falciparum (1)  ·  Seizures (1)

Broader conditions

Central Nervous System Diseases (10)  ·  Central Nervous System Infections (10)  ·  Infections (10)  ·  Nervous System Diseases (10)  ·  Parasitic Diseases (10)  ·  Central Nervous System Protozoal Infections (6)  ·  Protozoan Infections (6)  ·  Brain Diseases (5)  ·  Central Nervous System Helminthiasis (4)  ·  Cestode Infections (4)  ·  Cysticercosis (4)  ·  Helminthiasis (4)  ·  Mosquito-Borne Diseases (4)  ·  Vector Borne Diseases (4)

Interventions

Leucovorin (2)  ·  Pyrimethamine (2)  ·  oxfendazole (2)  ·  Azithromycin (1)  ·  Diazooxonorleucine (1)  ·  Levetiracetam (1)  ·  Mannitol (1)  ·  Sodium Chloride (1)  ·  Zidovudine (1)

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  National Institute of Mental Health (NIMH) (2)  ·  U.S. Army Medical Research and Development Command (2)  ·  Douglas Postels, MD, MS (1)  ·  Johns Hopkins Bloomberg School of Public Health (1)  ·  Pfizer (1)  ·  University of Rochester (1)

Countries

United States (7)  ·  Malawi (2)

Top investigators

Masahiro Fujita, M.D. (2)  ·  Peter J Weina, MD, PhD (2)  ·  B Luft (1)  ·  Douglas Postels, MD (1)  ·  Gretchen L Birbeck, M.D. (1)  ·  Luft B (1)  ·  Remington J (1)  ·  Robert H Gilman, MD (1)

Results publications

PMID 29749279, PMID 30745383, PMID 31672143, PMID 38279124, PMID 41748157, PMID 8615453, PMID 9364715, PMID 9840607

NIH funding

R01NS074409 (1)